相似文献
1
The good and evil of complement activation in HIV-1 infection.
Cell Mol Immunol. 2010 Sep;7(5):334-40. doi: 10.1038/cmi.2010.8. Epub 2010 Mar 15.
2
Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.
J Virol. 2015 Sep;89(18):9393-406. doi: 10.1128/JVI.01614-15. Epub 2015 Jul 1.
3
Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.
J Immunol. 2014 Oct 1;193(7):3577-89. doi: 10.4049/jimmunol.1303030. Epub 2014 Aug 22.
4
Humoral immunity to HIV-1: neutralization and beyond.
J Intern Med. 2007 Jul;262(1):5-25. doi: 10.1111/j.1365-2796.2007.01819.x.
5
A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement.
Virol J. 2010 Jun 29;7:142. doi: 10.1186/1743-422X-7-142.
6
Induction of complement-mediated lysis of HIV-1 by a combination of HIV-specific and HLA allotype-specific antibodies.
Immunol Lett. 2009 Sep 22;126(1-2):85-90. doi: 10.1016/j.imlet.2009.08.005. Epub 2009 Aug 19.
7
Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
Virology. 1994 Nov 1;204(2):609-15. doi: 10.1006/viro.1994.1575.
8
Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.
J Virol. 1995 Apr;69(4):2393-400. doi: 10.1128/JVI.69.4.2393-2400.1995.
9
Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
Virology. 1996 Dec 1;226(1):13-21. doi: 10.1006/viro.1996.0623.
10
HIV and human complement: mechanisms of interaction and biological implication.
Immunol Today. 1993 Sep;14(9):435-40. doi: 10.1016/0167-5699(93)90246-H.
引用本文的文献
1
Advantages of using complement components in preventive and therapeutic vaccine strategies for infectious and non-infectious diseases.
J R Soc Interface. 2025 Jul;22(228):20250138. doi: 10.1098/rsif.2025.0138. Epub 2025 Jul 2.
2
Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.
Pathogens. 2025 Feb 1;14(2):129. doi: 10.3390/pathogens14020129.
3
Enhanced complement activation and MAC formation accelerates severe COVID-19.
Cell Mol Life Sci. 2024 Sep 16;81(1):405. doi: 10.1007/s00018-024-05430-w.
4
Is the Complement System Dysregulated in Preeclampsia Comorbid with HIV Infection?
Int J Mol Sci. 2024 Jun 5;25(11):6232. doi: 10.3390/ijms25116232.
5
Emerging role of complement in COVID-19 and other respiratory virus diseases.
Cell Mol Life Sci. 2024 Feb 18;81(1):94. doi: 10.1007/s00018-024-05157-8.
6
HIV infection impairs the host response to Mycobacterium tuberculosis infection by altering surfactant protein D function in the human lung alveolar mucosa.
Mucosal Immunol. 2024 Jun;17(3):461-475. doi: 10.1016/j.mucimm.2023.12.003. Epub 2024 Jan 4.
7
Platelet and HIV Interactions and Their Contribution to Non-AIDS Comorbidities.
Biomolecules. 2023 Nov 2;13(11):1608. doi: 10.3390/biom13111608.
8
Is the central complement component C3 altered in the synergy of HIV infection and preeclampsia?
Eur J Obstet Gynecol Reprod Biol X. 2023 Oct 20;20:100257. doi: 10.1016/j.eurox.2023.100257. eCollection 2023 Dec.
9
Complement contributes to antibody-mediated protection against repeated SHIV challenge.
Proc Natl Acad Sci U S A. 2023 May 16;120(20):e2221247120. doi: 10.1073/pnas.2221247120. Epub 2023 May 8.
10
Nanobody-mediated complement activation to kill HIV-infected cells.
EMBO Mol Med. 2023 Apr 11;15(4):e16422. doi: 10.15252/emmm.202216422. Epub 2023 Feb 17.
本文引用的文献
1
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
J Immunol. 2010 Jan 1;184(1):359-68. doi: 10.4049/jimmunol.0902278. Epub 2009 Dec 2.
2
Association between mannose-binding lectin and HIV infection and progression in a Chinese population.
Mol Immunol. 2009 Dec;47(2-3):632-8. doi: 10.1016/j.molimm.2009.08.020. Epub 2009 Sep 30.
3
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.
4
A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement.
Virol J. 2009 Aug 12;6:123. doi: 10.1186/1743-422X-6-123.
5
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949.
6
Complement and antibodies: a dangerous liaison in HIV infection?
Vaccine. 2008 Dec 30;26 Suppl 8:I79-85. doi: 10.1016/j.vaccine.2008.11.050.
7
T cell responses generated by HIV vaccines in clinical trials.
Curr Opin HIV AIDS. 2008 May;3(3):375-9. doi: 10.1097/COH.0b013e3282fbaaa7.
8
Correlates of antibody-mediated protection against HIV infection.
Curr Opin HIV AIDS. 2008 May;3(3):368-74. doi: 10.1097/COH.0b013e3282f9ae79.
9
The challenge of finding a cure for HIV infection.
Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706.
10
Mechanisms of protection against rotavirus infection and disease.
Pediatr Infect Dis J. 2009 Mar;28(3 Suppl):S57-9. doi: 10.1097/INF.0b013e3181967c16.
Zotero 插件